arrow
M

Mohamed Elemary

saskatchewan cancer agency and university of saskatchewan
H指数:17
被引数:1,733

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cell Therapy Transplant Canada (CTTC) Consensus-Based Review for the Use of Supportive Care and Topical Therapies for Chronic Graft-Versus-Host Disease

细胞疗法移植加拿大(CTTC)关于慢性移植物抗宿主病支持性护理和局部疗法的共识性综述

2026-09-100
OA
A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants – a study from the Cell Therapy Transplant Canada/ Australasian Leukemia Lymphoma Group Consortium

一项随机试点试验,比较抗胸腺细胞球蛋白与抗胸腺细胞球蛋白加移植后环磷酰胺对匹配供体造血细胞移植中预防急性和慢性移植物抗宿主病的效果——加拿大细胞治疗移植/澳大利亚白血病淋巴瘤研究集团联盟的研究

2026-08-210
OAAI
Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma

G-CSF单药与预防性普乐沙福在 newly diagnosed multiple myeloma 自体外周血造血干细胞动员中的安全性与有效性

2025-12-010
PRE
Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival

真实世界中,关于重度预治疗且对糖皮质激素难治的慢性移植物抗宿主病患者接受belumosudil治疗的加拿大数据:治疗结局及无失败生存期的风险因素分析

2025-10-250
OA
Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment

内皮活化与应激指数(EASIX)作为预测鲁索利替尼治疗糖皮质激素难治性急性移植物抗宿主病的失败生物标志物

2025-09-140
OAAI
Real-World Efficacy of Belumosudil in Treating Fibrotic Symptom Burden in Chronic Gvhd: Modified Lee Symptom Score Assessment after Multiple Treatment Failures

Belumosudile在治疗慢性移植物抗宿主病纤维化症状负担中的真实世界疗效:多次治疗失败后的改良Lee症状评分评估

BLOOD
IF23.1
2024-11-050
PRE
International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update

移植和细胞治疗长期幸存者的筛查和预防实践的国际建议: 2023更新

2024-04-0115
OAAI
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
2022-08-188
OAAI
Revised 15-item MDS-specific frailty scale maintains prognostic potential

修订后的15项MDS特定虚弱量表可维持预后潜力

LEUKEMIA
IF13.4
2020-08-2812
PREAI
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

在接受非亲缘供体移植的血液系统恶性肿瘤患者中,抗胸腺细胞球蛋白在标准移植物抗宿主病预防中的应用与单独标准治疗的比较: 一项随机、开放标签、多中心、3期试验的最终分析

2020-02-0168
PREAI
An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring
LEUKEMIA
IF13.4
2019-12-0626
PREAI
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry

骨髓增生异常综合征对促红细胞生成素刺激剂反应的预测模型: 来自加拿大MDS患者登记处

2017-10-0314
PREAI